Assembly Biosciences
ASMB
107 hedge funds and large institutions have $789M invested in Assembly Biosciences in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 12 closing their positions.
130% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $8.87M
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
12% more capital invested
Capital invested by funds: $703M → $789M (+$86.1M)
9% more funds holding
Funds holding: 98 → 107 (+9)
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0.11% more ownership
Funds ownership: 6.5% → 6.61% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$29M |
| 2 |
Jennison Associates
New York
|
+$16.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.27M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$7.75M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$6.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$11.3M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$6.66M |
| 4 |
Millennium Management
New York
|
-$5.27M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.02M |
ASMB Hedge Fund Activity: Q1 2018 in Review
107 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q1 2018, worth a combined $789M — up 12% from $703M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ASMB positions and 12 closed out — a net gain of 11 holders — while 37 added to existing stakes and 36 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $29M. The largest seller was OrbiMed, cutting an estimated $24.6M.
- 107 institutional investors held Assembly Biosciences (ASMB) as of Q1 2018, up from 98 in Q4 2017.
- Funds reported $789M of Assembly Biosciences stock for Q1 2018, up 12% quarter-over-quarter.
- 23 funds opened new Assembly Biosciences positions in Q1 2018 and 12 closed out, a net change of +11 holders.
- The largest Assembly Biosciences buyer in Q1 2018 was Janus Henderson Group, an estimated $29M added.
- The largest Assembly Biosciences seller in Q1 2018 was OrbiMed, an estimated $24.6M sold.
Based on aggregated 13F filings for Q1 2018.